Application
Fig1: ICC staining Survivin in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Survivin antibody. Counter stained with hematoxylin.Application
Fig3: Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-Survivin antibody. Counter stained with hematoxylin.Application
Fig4: Flow cytometric analysis of Hela cells with Survivin antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody.| Product Name | Survivin [SP07-06] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | API4 antibody Apoptosis inhibitor 4 antibody Apoptosis inhibitor survivin antibody Apoptosis inhibitor4 antibody Baculoviral IAP repeat containing 5 antibody Baculoviral IAP repeat containing protein 5 antibody Baculoviral IAP repeat-containing protein 5 antibody BIRC 5 antibody BIRC5 antibody BIRC5_HUMAN antibody EPR 1 antibody IAP4 antibody Survivin variant 3 alpha antibody SVV antibody TIAP antibody |
| Product description | The baculovirus protein p35 inhibits virally-induced apoptosis of invertebrate and mammalian cells and may function to impair the clearing of virally infected cells by the immune system of the host. This is accomplished at least in part by the ability of p35 to block both TNF- and FAS-mediated apoptosis through the inhibition of the ICE family of serine proteases. Two mammalian homologs of baculovirus p35, referred to as inhibitor of apoptosis protein (IAP) 1 and 2, share an amino-terminal baculovirus IAP repeat (BIR) motif and a carboxy-terminal RING finger. Although the c-IAPs do not directly associate with the TNF receptor (TNF-R), they efficiently block TNF-mediated apoptosis through their interaction with the downstream TNF-R effectors, TRAF1 and TRAF2. Additional IAP family members include ILP (for IAP-like protein) and survivin. ILP inhibits activated caspase-3, leading to the resistance of FAS-mediated apoptosis. Survivin (also designated TIAP) is expressed during the G2/M phase of the cell cycle and associates with microtubules of the mitotic spindle. Increased caspase-3 activity is detected when a disruption of survivin-microtubule interactions occurs. |
| Immunogen | recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG |
| Host Species | Recombinant rabbit |
| Tested Applications | WBICC/IFIHCFC |
| WB:1:1,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:100 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | API4 antibody Apoptosis inhibitor 4 antibody Apoptosis inhibitor survivin antibody Apoptosis inhibitor4 antibody Baculoviral IAP repeat containing 5 antibody Baculoviral IAP repeat containing protein 5 antibody Baculoviral IAP repeat-containing protein 5 antibody BIRC 5 antibody BIRC5 antibody BIRC5_HUMAN antibody EPR 1 antibody IAP4 antibody Survivin variant 3 alpha antibody SVV antibody TIAP antibody |
|---|---|
| Molecular Weight(MW) | 16 kDa |
| Cellular Localization | Cytoplasm, Nucleus, Chromosome, Midbody. |
| SwissProt ID | O15392 |
|---|
Application
Fig1: ICC staining Survivin in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Survivin antibody. Counter stained with hematoxylin.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-Survivin antibody. Counter stained with hematoxylin.
Application
Fig4: Flow cytometric analysis of Hela cells with Survivin antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody.| Positive Control | Hela, human tonsil tissue, human breast carcinoma tissue. |
|---|---|
| Application Notes | WB:1:1,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:100 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
